Cyramza 500 mg Injection
2.918,54$
2.276,45$
Cyramza 500 mg injection is a targeted monoclonal antibody treatment designed for specific types of cancer, including gastric and lung cancers. This innovative therapy functions by blocking the vascular endothelial growth factor receptor 2 (VEGFR2), a key protein that promotes the development of blood vessels feeding tumors. By effectively inhibiting VEGFR2, Cyramza helps to slow or potentially halt the progression of cancer cells, enhancing treatment outcomes for patients. It is crucial to monitor for potential side effects such as hypertension and bleeding, as well as to consider its use in conjunction with other cancer therapies. Patients should be aware of contraindications and discuss their medical history with healthcare providers to ensure safe administration. As a part of a comprehensive cancer treatment plan, Cyramza represents a vital option for individuals facing aggressive malignancies. Always consult with your oncologist for personalized advice and to understand the full benefits and risks associated with Cyramza.
Cantidad
Active Pharmaceutical Ingredient
Uses
• Cyramza 500 mg injection is primarily used in the treatment of stomach cancer, particularly in cases where the disease has progressed or is advanced. This medication works by targeting specific pathways that cancer cells utilize to grow and spread. Patients receiving Cyramza 500 mg injection may experience improved outcomes when combined with other cancer therapies. It is often prescribed when other treatments have not been effective.
• Another significant application of Cyramza 500 mg injection is for colorectal cancer, especially in patients with metastatic disease. The injection helps inhibit tumor growth and can be part of a comprehensive treatment plan. Oncologists may recommend Cyramza 500 mg injection for patients whose cancer has spread to other parts of the body. This targeted approach aims to enhance the effectiveness of existing treatments.
• Cyramza 500 mg injection is also indicated for non-small cell lung cancer, particularly in patients with advanced disease. The drug helps to block the vascular endothelial growth factor (VEGF) pathway, which is crucial for tumor blood supply. By using Cyramza 500 mg injection, healthcare providers aim to slow disease progression in affected individuals. This treatment option is often explored after prior therapies have been attempted.
• Additionally, Cyramza 500 mg injection is utilized in the management of hepatocellular carcinoma, a common type of liver cancer. This medication assists in controlling the growth of tumors by targeting specific signaling pathways. Physicians may consider Cyramza 500 mg injection for patients who are not candidates for surgery or other local treatments. It plays a vital role in the overall therapeutic strategy for managing liver cancer.
Benefits
Gastric cancer: Gastric Cancer: Cyramza 500 mg Injection may be used alone or in combination with other chemotherapy drugs to treat advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) cancer. Cyramza 500 mg can help slow down disease progression and improve overall survival in patients with these types of cancer.
Colorectal cancer: Cyramza 500 mg Injection may be used with other chemotherapy medicines to treat metastatic colorectal cancer that has progressed after prior therapy. Cyramza Injection can delay tumor growth and extend survival in these patients.
Non-small cell lung cancer: Cyramza 500 mg Injection is prescribed for patients with advanced NSCLC, particularly those with certain molecular characteristics. Cyramza 500 mg may be used in combination with other anticancer medications to improve treatment outcomes.
Hepatocellular carcinoma (Liver Cancer): Cyramza 500 mg Injection is used for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma who have a serum alpha-fetoprotein (AFP) of ≥ 400 ng/ml and who have been previously treated with sorafenib.
Side Effects
Like all medicines, Cyramza 500 mg Injection may cause side effects such as high blood pressure, fatigue, nausea, vomiting, and diarrhoea. Tell your doctor if you have high blood pressure, bleeding problems, liver disease, kidney disease, lung cancer, or are going to have surgery before taking this medication. This medicine is not recommended for adolescents or children under 18 years of age.
Most Common Side Effects
• Sore throat
• Hypertension
• Nausea
• Vomiting
• Diarrhea
• Headache
• Chills
• Fever
• Fainting
• Nervousness
• Shivering
• Weakness
• Pounding in ears
• Seizures
Common Side Effects
• Visual Changes
• Rashes
• Dry mouth
• Feeling of Dehydration
• Decreased Urine
• Dizziness
• Loss of Appetite
• Dry Cough
• Productive Cough
• Painful Urination
• Pale skin
• Abdominal Cramps
• Slurred Speech
• Sweating
• Blurred Vision
• feeling of Numbness
How To Use
Cyramza 500 mg Injection should be given under the supervision of your healthcare professional as an infusion directly into a vein or intravenously. The dosage and duration of your medication will depend on many factors such as the severity of your illness, type of illness, age, weight, gender and other medical conditions. It is a good idea to tell your doctor or health care professional about all other medicines you are taking or are being treated with. Avoid using this medicine if you are pregnant or breastfeeding as safety in these patients has not been established.
Safety Advice
• Alcohol: It is generally recommended that patients taking {Product_namee_two} should avoid or reduce their alcohol intake as alcohol can increase the risk of liver damage and worsen any liver-related side effects of this medicine.
• Kidney: Cyramza 500 mg Injection should be used with extreme caution in patients with kidney disease due to the increased risk of worsening the patient's condition. Close monitoring of kidney function is essential while taking this Cyramza 500 mg. Appropriate dose adjustment or substitution with a suitable alternative may be required in some cases depending on the clinical condition of the patient.
• Breastfeeding: The excretion of Cyramza 500 mg Injection in human milk remains uncertain. It is expected that excretion in milk and oral absorption will be minimal. Due to the potential risk to breastfeeding infants, it is recommended that breastfeeding be discontinued during treatment with Cyramza 500 mg and for at least three months after the remaining dose.
• Liver: Cyramza 500 mg Injection should be used with extreme caution in patients with liver disease due to the increased risk of worsening the patient's condition. Close monitoring of liver function is essential while taking this medicine. Appropriate dose adjustment or substitution with a suitable alternative may be required in some cases depending on the clinical condition of the patient.
• Pregnancy: Cyramza 500 mg Injection is not recommended during pregnancy or in women of childbearing potential who are not using contraception. Women of childbearing potential should be advised not to become pregnant while taking Cyramza Injection and should be counselled about the potential hazards to pregnancy and the foetus. Women of childbearing potential should use effective contraception during and for up to 3 months after the last dose of Cyramza 500 mg Injection.
• Driving: Cyramza 500 mg Injection has no or negligible effect on the ability to drive or use machinery. If patients experience symptoms that affect their ability to concentrate and react, it is recommended that they do not drive or use machinery until the effects have subsided.